|
|
"Developing Novel Drugs Targeting Cancer Stem Cells" - Topic 255
|
N43CO900071-000
|
$221,770
|
$110,885
|
Li, Chian
|
BOSTON BIOMEDICAL, INC.:1166738
|
|
|
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
|
5R01CA116019-03
|
$295,736
|
$73,934
|
AKHURST, ROSEMARY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
14-3-3zeta in ErbB2 Mediated Mammary Carcinogenesis
|
5R01CA112567-05
|
$254,494
|
$254,494
|
Yu, Dihua
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrent
|
1R21CA139814-01
|
$236,417
|
$236,417
|
BENARD, FRANCOIS
|
BRITISH COLUMBIA CANCER AGENCY
|
|
|
3D-adhesion stromagenesis in cancer permissiveness
|
5R01CA113451-04
|
$235,778
|
$235,778
|
CUKIERMAN, EDNA
|
INSTITUTE FOR CANCER RESEARCH
|
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
|
5R43CA132257-02
|
$131,674
|
$65,837
|
MORGAN, Lee
|
DEKK-TEC, INC.
|
|
|
A Cellular and Molecular Analysis of the Intravasation Step in Tumor Metastasis
|
5R01CA129484-02
|
$393,213
|
$393,213
|
QUIGLEY, JAMES
|
SCRIPPS RESEARCH INSTITUTE
|
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-03
|
$189,600
|
$189,600
|
HOLMEN, SHERI
|
NEVADA CANCER INSTITUTE
|
|
|
A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
|
5R01CA072038-12
|
$300,198
|
$99,065
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A laminin peptide increases breast cancer bone metastasis
|
5K22CA116258-03
|
$153,144
|
$153,144
|
KOBLINSKI, JENNIFER
|
NORTHWESTERN UNIVERSITY
|
|
|
A microfluidic platform to study the effects of chemokine gradients on prostate c
|
1R15CA133623-01A1
|
$205,407
|
$205,407
|
CHIAO, JUNG-CHIH
|
UNIVERSITY OF TEXAS ARLINGTON
|
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$109,726
|
$109,726
|
Kelly, Kathleen
|
CCR (NCI)
|
|
|
A mouse model for p120 downregulation in cancer
|
5R01CA111947-05
|
$287,369
|
$287,369
|
REYNOLDS, ALBERT
|
VANDERBILT UNIVERSITY
|
|
|
A Mouse model of TGFbeta1 and ras oncogene interactions
|
5R01CA122109-04
|
$239,514
|
$59,879
|
GLICK, ADAM
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
|
A novel function of TIMP-1
|
5R01CA089113-07
|
$269,442
|
$67,361
|
KIM, HYEONG-REH
|
WAYNE STATE UNIVERSITY
|
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
5R01CA104035-05
|
$280,899
|
$140,450
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Novel Oncolytic HSP Vaccine for Systemic Tumor Therapy
|
5R01CA100841-04
|
$224,748
|
$112,374
|
HUANG, XUE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
A novel osteopontin fragment as a diagnostic/prognostic cancer plasma biomarker
|
5R21CA129849-02
|
$202,902
|
$50,726
|
Liaw, Lucy
|
MAINE MEDICAL CENTER
|
|
|
A novel preclinical model of spontaneous metastasis
|
ZIA BC 011167
|
$340,155
|
$238,108
|
Merlino, Glenn
|
CCR (NCI)
|
|
|
A Novel Regulator of Cancer Cell Migration and Invasion
|
5R01CA115706-04
|
$195,792
|
$195,792
|
ALAHARI, SURESH
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
|
A Pathway of Tumor Suppression
|
5R01CA047296-22
|
$236,943
|
$59,236
|
Lozano, Guillermina
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
A Pb-212 Generator Using Resistant Substrate and Rn Cold Trapping
|
1R41CA135857-01A1
|
$111,339
|
$55,670
|
Ehrhardt, Gary
|
ALPHAMED, INC
|
|
|
A Phase I/II Clinical Trial of Intravenous (I.V.) Calcitriol with Fixed Doses of
|
5R21CA128193-03
|
$378,381
|
$378,381
|
RAMNATH, NITHYA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
|
A phase II study of IPI-504 in metastatic hormone refractory prostate cancer
|
5R21CA128352-02
|
$263,979
|
$263,979
|
oh, william
|
DANA-FARBER CANCER INSTITUTE
|
|
|
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
|
1R21CA139473-01A1
|
$343,200
|
$343,200
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
|
A primary human xenograft model of pancreatic cancer.
|
1R03CA141245-01
|
$75,750
|
$75,750
|
BAUER, TODD
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
|
|
A program of immune-based treatments for cancer
|
5K24CA093670-07
|
$181,546
|
$45,387
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
|
A Risk Prediction Model for Colorectal Cancer Screening
|
5R01CA131197-02
|
$528,903
|
$528,903
|
SCHROY, PAUL
|
BOSTON MEDICAL CENTER
|
|
|
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
|
5R01CA127735-02
|
$312,288
|
$312,288
|
SHENG, SHIJIE
|
WAYNE STATE UNIVERSITY
|
|
|
A Structure/function Analysis of a Tumor Specific Protein
|
5R01CA121289-03
|
$287,850
|
$287,850
|
MALKAS, LINDA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
|
2U01CA084244-11
|
$737,257
|
$737,257
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
Abi pathway in Breast Cancer Metastasis
|
1R21CA133597-01A1
|
$163,350
|
$163,350
|
DAI, ZONGHAN
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
|
Abl kinases in growth factor signaling, motility and invasion
|
5R01CA116784-03
|
$268,384
|
$268,384
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S1
|
$114,606
|
$9,168
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S3
|
$100,000
|
$8,000
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
5P30CA016520-34
|
$7,326,647
|
$586,132
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
ACOSOG Central Specimen Bank
|
5U24CA114736-05
|
$408,191
|
$40,819
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
|
Acoustic Radiation Force Imaging of Colorectal Tissues
|
5R01CA114075-05
|
$282,727
|
$28,273
|
NIGHTINGALE, KATHRYN
|
DUKE UNIVERSITY
|
|
|
Activated nano-sized MR contrast agents for imaging of tumor proteolytic activity
|
1R21CA133288-01A1
|
$180,400
|
$180,400
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
5P01CA128913-02
|
$1,752,897
|
$315,521
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
Adhesion signaling by a novel mitotic substrate of src
|
5R01CA113952-05
|
$255,337
|
$127,669
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
Adhesive Regulation During Cell Migration
|
5R01CA085862-10
|
$272,487
|
$272,487
|
HUTTENLOCHER, ANNA
|
UNIVERSITY OF WISCONSIN MADISON
|
|
|
Adiposity and Outcomes of Clinically Localized Prostate Cancer
|
1R01CA129140-01A2
|
$660,462
|
$660,462
|
Freeman, Vincent
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
|
ADJUVANT TRIAL WITH SOY AFTER RADICAL PROSTATECTOMY
|
5R01CA116195-05
|
$245,369
|
$245,369
|
BOSLAND, MAARTEN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
|
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
|
1R01CA134844-01A2
|
$321,841
|
$321,841
|
MITCHELL, DUANE
|
DUKE UNIVERSITY
|
|
|
Adoptive T Cell Therapy Following CD25 Lymphodepletion
|
1R21CA137647-01A2
|
$351,887
|
$351,887
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Advanced Ultrasonic Evaluation of Sentinel Lymph Nodes
|
5R01CA100183-04
|
$252,162
|
$252,162
|
Feleppa, Ernest
|
RIVERSIDE RESEARCH INSTITUTE
|
|
|
AEG-1: Novel Gene Involved in Malignant Glioma
|
1R01CA134721-01A1
|
$310,213
|
$310,213
|
FISHER, PAUL
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
AGAP2 regulates membrane trafficking and migaration of glioblastoma cells
|
1K22CA124578-01A2
|
$192,024
|
$192,024
|
NIE, ZHONGZHEN
|
UNIVERSITY OF FLORIDA
|
|
|
Agents for Specific NMR and SQUID Imaging of Prostate Cancer
|
5R01CA123194-03
|
$454,956
|
$454,956
|
Sillerud, Laurel
|
UNIVERSITY OF NEW MEXICO
|
|
Total relevant funding to Metastasis for this search: $387,260,786
|
